% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koistinen:186588,
      author       = {H. Koistinen and R.-M. Kovanen and M. D. Hollenberg and A.
                      Dufour and E. S. Radisky and U.-H. Stenman and J. Batra and
                      J. Clements and J. D. Hooper and E. Diamandis and O.
                      Schilling$^*$ and A. Rannikko and T. Mirtti},
      title        = {{T}he roles of proteases in prostate cancer.},
      journal      = {IUBMB life},
      volume       = {75},
      number       = {6},
      issn         = {1521-6543},
      address      = {Weinheim [u.a.]},
      publisher    = {Wiley-VCH},
      reportid     = {DKFZ-2023-00024},
      pages        = {493-513},
      year         = {2023},
      note         = {2023 Jun;75(6):493-513},
      abstract     = {Since the proposition of the pro-invasive activity of
                      proteolytic enzymes over 70 years ago, several roles for
                      proteases in cancer progression have been established. About
                      half of the 473 active human proteases are expressed in the
                      prostate and many of the most well-characterized members of
                      this enzyme family are regulated by androgens, hormones
                      essential for development of prostate cancer. Most notably,
                      several kallikrein-related peptidases, including KLK3
                      (prostate-specific antigen, PSA), the most well-known
                      prostate cancer marker, and type II transmembrane serine
                      proteases, such as TMPRSS2 and matriptase, have been
                      extensively studied and found to promote prostate cancer
                      progression. Recent findings also suggest a critical role
                      for proteases in the development of advanced and aggressive
                      castration-resistant prostate cancer (CRPC). Perhaps the
                      most intriguing evidence for this role comes from studies
                      showing that the protease-activated transmembrane proteins,
                      Notch and CDCP1, are associated with the development of
                      CRPC. Here, we review the roles of proteases in prostate
                      cancer, with a special focus on their regulation by
                      androgens.},
      subtyp        = {Review Article},
      keywords     = {AR (Other) / CDCP1 (Other) / CUB domain-containing protein
                      1 (Other) / FAP (Other) / KLK (Other) / MMP (Other) / Notch
                      (Other) / PAR (Other) / TMPRSS2 (Other) / androgen (Other) /
                      androgen receptor (Other) / fibroblast activation protein
                      (Other) / hepsin (Other) / kallikrein-related peptidases
                      (Other) / matriptase (Other) / matrix metalloproteinase
                      (Other) / peptidases (Other) / prostate cancer (Other) /
                      protease-activated receptor (Other) / proteases (Other) /
                      trypsin (Other) / uPA (Other) / urokinase-type plasminogen
                      activator (Other)},
      cin          = {FR01},
      ddc          = {570},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36598826},
      doi          = {10.1002/iub.2700},
      url          = {https://inrepo02.dkfz.de/record/186588},
}